The DOI matches its Crossref record.
Immune Responses to Gene Product of Inducible Promoters
Abstract
Efficient gene transfer has been achieved in several animal models using different vector systems, leading to stable transgene expression. The tight control of this expression is now an important outcome for the field of gene therapy. Such regulation is likely to be required for therapeutic applications and in some instances for safety reasons. For this purpose, several regulatable systems depending on small molecules have been developed. Among these, the tetracycline and the rapamycin dependent systems have been largely used. However, if long-term regulation of the transgene has been obtained in small animal models using these inducible systems, when translational studies were initiated in larger animals, the development of an immune response against proteins involved in transgene regulation were often observed. Such immune response was especially documented when using the TetOn tetracycline regulatable system in nonhuman primates (NHP). Humoral and destructive cellular immune responses against the transactivator involved in this regulation system were documented in a large majority of NHP leading to the complete loss of the transgene regulation and expression. This review will describe the immune responses observed in these different model systems applied for transgene regulation. Focus will be finally given on future directions in which such immune responses might be surmounted, enabling long-term transgene regulation in future clinical developments of gene transfer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In vivo application of the Tet-On systems can be complicated by immune responses against rtTA, as reported in rodents and non-human primates.
“In vivo application of the systems can be complicated by immune responses against rtTA, as reported in rodents and non-human primates [73-78].”
From Tet-On Systems For Doxycycline-inducible Gene Expression (2016) · cites this paper as [78]
Immune responses against rtTA, both cellular and humoral, are dependent on the target tissue and vector delivery route.
“These immune responses, both cellular and humoral, are dependent on the target tissue and vector delivery route (reviewed in [78]).”
From Tet-On Systems For Doxycycline-inducible Gene Expression (2016) · cites this paper as [78]
Citations
Cited by
Sorted by citations
Tet-On Systems For Doxycycline-inducible Gene Expression
T. Das, A., Tenenbaum, L., & Berkhout, B. (2016) · Current Gene Therapy · doi:10.2174/1566523216666160524144041 · Cited by 434
“In vivo application of the systems can be complicated by immune responses against rtTA, as reported in rodents and non-human primates [73-78].”
BackgroundMartino, A. T., Nayak, S., Hoffman, B. E., Cooper, M., Liao, G., Markusic, D. M., Byrne, B. J., Terhorst, C., & Herzog, R. W. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006376 · Cited by 54
Barriers for retinal gene therapy: separating fact from fiction.
Kumar-Singh, R. (2008) · Vision Research · doi:10.1016/j.visres.2008.05.005 · Cited by 43
Metadata
- Authors
- Guiner, C., Stieger, K., Snyder, R., Rolling, F., & Moullier, P.
- Affiliations
- Inserm (FR)
- Venue
- Current Gene Therapy
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2007-10-01
- Volume
- 7
- Issue
- 5
- Pages
- 334-346
- ISSN
- 1566-5232 (ISSN-L)
- OpenAlex
- W2141908220
- Cited by
- 46
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 4 · 2023: 2 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 3 · 2017: 1 · 2016: 3 · 2015: 1 · 2014: 4 · 2013: 4 · 2012: 3
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Gene Therapy (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons - East Tennessee State University (East Tennessee State University) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Animal Genetics and Reproduction
- Keywords
- inducible promoters, immune response, transcriptional activator, transgene expression regulation, non-human primates, humoral immune response, cell-mediated immunity, gene delivery vectors, long-term transgene expression
- MeSH terms
- Animals, Anti-Bacterial Agents, Antibody Formation, Gene Expression Regulation, Genetic Vectors, Humans, Immune Tolerance, Immunity, Cellular, Immunosuppressive Agents, Promoter Regions, Genetic, Repressor Proteins, Tetracycline, Genetic Therapy, Trans-Activators, Gene Transfer Techniques, Transgenes, Sirolimus, Models, Animal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review